Janssen Search
Search results
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Dec 09, 2022 United States RARITAN, N.J., December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer
Oct 22, 2023 Spain Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, October 22, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today ...
Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
Apr 21, 2023 United States Click to Access Audio Press Release Important new data on Janssen’s investigational gene therapy portfolio, including botaretigene sparoparvovec (bota-vec) and JNJ-1887, will be presented RARITAN, N.J., April 21, 2023 – The ...
Janssen to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2023 Annual Meeting
Oct 03, 2023 United States Click to Access Audio Press Release Five abstracts to be presented, including new real-world research and data on Janssen’s investigational gene therapy JNJ-1887 RARITAN, N.J., October 3, 2023 – The Janssen Pharmaceutical ...
Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
Jun 05, 2023 United States More than 60 percent of patients achieved an overall response and 45.5 percent of patients achieved a complete response or better by nearly five months Additional data highlights strong efficacy with biweekly TECVAYLI ® dosing ...
Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA
May 23, 2024 PALOMA-3 presentation of subcutaneous amivantamab and lazertinib selected to showcase cutting-edge approaches in lung cancer during prestigious "Best of ASCO" program New data showcase first- and-best-in-class, complementary ...
Janssen to Highlight Latest Research from Nipocalimab Clinical Development Program to Address Unmet Need in Myasthenia Gravis at AANEM 2023 Meeting
Oct 16, 2023 United States Data presentations reinforce potential for rapid, deep, and sustained efficacy with treatment and demonstrate how the unique immuno-selectivity of the compound may allow for greater targeting across a wide range of autoantibody ...
Health Canada Authorizes IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination with Venetoclax for Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Mar 24, 2023 Canada All-oral, once-daily, fixed-duration combination regimen authorized for first-line treatment of CLL TORONTO, March 23, 2023- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a ...
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
Apr 30, 2023 United States Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson ...
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Dec 21, 2023 Belgium The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress [1] Lazertinib is a highly selective, central nervous system-penetrant, ...